ECM
IOVA icon

Element Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Element Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-230,625
Closed -$2.04M – 891
2018
Q4 		$2.04M Buy
230,625
+201,697
+697% +$1.95M 0.06% 217
2018
Q3 		$325K Buy
28,928
+10,494
+57% +$149K 0.01% 568
2018
Q2 		$236K Buy
+18,434
New +$269K 0.01% 652

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Element Capital Management's IOVA Position: Q1 2019 in Review

Element Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2019, closing a stake of 230,625 shares — an estimated $2.04M sold.

Element Capital Management first reported a position in IOVA in Q2 2018 and held it in 3 quarters. The position peaked at $2.04M in Q4 2018. 153 funds tracked by Wall St. Rank hold IOVA as of Q1 2019.

  • Element Capital Management reported no remaining Iovance Biotherapeutics position as of Q1 2019 after selling out during the quarter.
  • Element Capital Management sold 230,625 Iovance Biotherapeutics shares in Q1 2019, an estimated $2.04M.
  • Element Capital Management first reported a position in Iovance Biotherapeutics in Q2 2018 and held it in 3 quarters.
  • Element Capital Management's Iovance Biotherapeutics position peaked at $2.04M in Q4 2018.
  • 153 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2019.

Based on Element Capital Management's 13F filing for Q1 2019, filed 13 May 2019.